Amgen Inc. (AMGN)
Nasdaq · Thousand Oaks, California, USA · Founded 1980 · CEO Robert Bradway
Valuation summary
$353.62 fair value versus $438.82 in the market, a difference of -19.4%. Rated Reduce.
| Fair value per share | $353.62 |
| Current share price | $438.82 |
| Upside / downside | -19.4% |
| Bear case | $222.23 |
| Bull case | $538.51 |
| Discount rate (WACC) | 8.6% |
| Terminal growth | 2.40% |
| Market capitalisation | $237B |
| EV / Sales | 7.2x |
About Amgen Inc.
Founded in 1980 as Applied Molecular Genetics in Thousand Oaks, California, one of the original biotechnology companies. Robert Bradway has been CEO since 2012. Amgen's portfolio spans Repatha for cholesterol, Prolia and Evenity for osteoporosis, Tezspire for asthma, the oncology drug Blincyto, and a large biosimilars business. Its 2023 acquisition of Horizon Therapeutics added Tepezza for thyroid eye disease and Krystexxa for gout. MariTide, a monthly injectable obesity drug, is the company's most-watched pipeline asset.
Investment case
- MariTide's monthly dosing would be a genuine differentiator against weekly GLP-1 injections.
- Rare disease assets from Horizon carry high prices and limited competition.
- Biosimilars provide a growing revenue stream that benefits as branded biologics lose exclusivity.
Key risks
- Around $52B of net debt from the Horizon deal is high and constrains further business development.
- Prolia and other mature products face biosimilar erosion of their own.
- MariTide is a binary event — the obesity market is unforgiving and Lilly and Novo are far ahead.
Recent developments
- 2026-09-08 · Shares fell 10% to $394.38 as Novartis's pelacarsen failure clouded the Lp(a) class, overshadowing a Phase 3 overall-survival win for Imdelltra in small cell lung cancer. source
- 2026-08-04 · Q2 revenue up 10% to $10.1B, non-GAAP EPS $6.29; 2026 guidance raised to $38.2-39.4B revenue and $22.30-23.50 non-GAAP EPS. source
Revenue by segment
| General Medicine | 42% |
| Oncology | 24% |
| Rare Disease (Horizon) | 22% |
| Biosimilars & Other | 12% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $41.7B | $11.8B |
| Year 2 | $45.1B | $12.4B |
| Year 3 | $48.7B | $13.0B |
| Year 4 | $52.7B | $13.6B |
| Year 5 | $57.0B | $14.2B |
What the street says
Split between those buying the MariTide option and those focused on the debt load and mature base business. A guidance raise in August 2026 lifted the shares 8.5% in a week, but they fell 10% on 8 September when Novartis's Lp(a) trial failure cast doubt on the class that includes Amgen's olpasiran.
Comparable companies: GILD · DHR · TMO · NVO · ABBV · VRTX · AZN · BMY
Open the interactive model, price chart and sensitivity grid →